Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Golden State Medical Supply unit-of-use alliance with CibaGeneva involves 50 products.

  • News

Executive Summary

GOLDEN STATE MEDICAL SUPPLY EXCLUSIVE UNIT-OF-USE AGREEMENT WITH CIBAGENEVA involves 50 products in the first phase of the alliance, inaugurated in February. CibaGeneva generics are being packaged into 30s, 60s and 90s unit-of-use containers for the retail, institutional and HMO pharmacy markets. The Valencia, Calif. unit-of-use repackager and wholesaler is positioning the CibaGeneva products as a way to provide retailers more time for counseling and ancillary pharmacy services. "The label and precounted product will save the pharmacists time in dispensing prescriptions," GSMS said. "In addition, the pharmacists will also be able to focus on other ancillary services such as glucose testing or special compounding."

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS027907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By